INCREASE随机对照试验:干预提升认知储备以延迟阿尔茨海默病症状表达的研究原理、设计与方案
INCREASE是一项随机对照试验,计划纳入90名≥65岁非痴呆社区居住成人,按淀粉样蛋白PET SUVr分层随机分配至药物治疗管理(MTM)干预组或对照组,随访12个月。研究评估MTM减少不适当用药、提升认知储备并最终延迟症状性阿尔茨海默病(AD)的疗效,主要结局包括用药适当性(MAI)、认知测试(TMTB、MoCA、CVLT)和健康状态(SF-36)。
要点
- MTM干预旨在减少不适当用药以提升认知储备,可能延迟症状性AD。
- 研究采用淀粉样蛋白PET SUVr分层随机,随访12个月评估认知与用药变化。
- 基线Aβ SUVr用于分析临床前AD病理对认知储备变化评分的影响。
核心结论
- INCREASE试验旨在检验MTM干预减少不适当用药、提升认知储备并延迟症状性AD的疗效。
研究设计与样本
- 随机对照试验,计划纳入90名≥65岁非痴呆社区居住成人,按Aβ PET SUVr分层随机分配至MTM干预或对照,随访12个月。
主要发现
- 原文未报告结果。
关键数值与推荐
- 纳入标准:≥65岁、非痴呆、社区居住成人,共90名。
- 主要结局包括用药适当性(MAI)、TMTB、MoCA、CVLT得分及SF-36健康状态。
- 认知储备变化评分(CRCS)定义为基线与随访时东莨菪碱挑战与否的认知得分差值。
- 基线Aβ SUVr用于分析临床前AD病理对CRCS的影响及淀粉样蛋白负荷与不适当用药的交互作用。
临床怎么用
- 针对老年非痴呆人群,MTM干预可能通过优化用药方案提升认知储备,但需待试验结果验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The course of Alzheimer's disease (AD) includes a 10-20-year preclinical period with progressive accumulation of amyloid β (Aβ) plaques and neurofibrillary tangles in the absence of symptomatic cognitive or functional decline. The duration of this preclinical stage in part depends on the rate of pathologic progression, which is offset by compensatory mechanisms, referred to as cognitive reserve (CR). Comorbid medical conditions, psychosocial stressors, and inappropriate medication use may lower CR, hastening the onset of symptomatic AD. Here, we describe a randomized controlled trial (RCT) designed to test the efficacy of a medication therapy management (MTM) intervention to reduce inappropriate medication use, bolster cognitive reserve, and ultimately delay symptomatic AD. METHODS/DESIGN: Our study aims to enroll 90 non-demented community-dwelling adults ≥ 65 years of age. Participants will undergo positron emission tomography (PET) scans, measuring Aβ levels using standardized uptake value ratios (SUVr). Participants will be randomly assigned to MTM intervention or control, stratified by Aβ levels, and followed for 12 months via in-person and telephone visits. Outcomes of interest include: (1) medication appropriateness (measured with the Medication Appropriateness Index (MAI)); (2) scores from Trail Making Test B (TMTB), Montreal Cognitive Assessment (MoCA), and California Verbal Learning Test (CVLT); (3) perceived health status (measured with the SF-36). We will also evaluate pre- to post-intervention change in: (1) use of inappropriate medications as measured by MAI; 2) CR Change Score (CRCS), defined as the difference in scopolamine-challenged vs unchallenged cognitive scores at baseline and follow-up. Baseline Aβ SUVr will be used to examine the relative impact of preclinical AD (pAD) pathology on CRCS, as well as the interplay of amyloid burden with inappropriate medication use. DISCUSSION: This manuscript describes the protocol of INCREASE ("INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression"): a randomized controlled trial that investigates the impact of deprescribing inappropriate medications and optimizing medication regimens on potentially delaying the onset of symptomatic AD and AD-related dementias. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02849639. Registered on 29 July 2016.
引用
- Moga DC, Beech BF, Abner EL, et al. INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression (INCREASE), a randomized controlled trial: rationale, study design, and protocol. Trials. 2019. PMID: 31888732. doi:10.1186/s13063-019-3993-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。